Typing of pneumococcal surface protein A (PspA) in Streptococcus pneumoniae isolated during epidemiological surveillance in Brazil:: towards novel pneumococcal protein vaccines

被引:44
作者
Brandileone, MCC
Andrade, ALSS
Teles, EM
Zanella, RC
Yara, TI
Di Fabio, JL
Hollingshead, SK
机构
[1] Adolfo Lutz Inst, Bacteriol Branch, Secretary Hlth State Sao Paulo, BR-01246902 Sao Paulo, Brazil
[2] Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Goiania, Go, Brazil
[3] Fiocruz MS, Biomanguinhos, BR-21045900 Rio De Janeiro, Brazil
[4] PAHO, Technol & Hlth Serv Delivery, Washington, DC USA
[5] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA
关键词
Streptococcus pneumoniae; PspA; vaccine;
D O I
10.1016/j.vaccine.2004.04.009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Pneumococcal protein vaccine based on pneumococcal surface protein A (PspA) is in development with the potential to offer broad range of protection against different strains. We have investigated the frequency of PspA family I (Fam1) and family 2 (Fam2) proteins among Streptococcus pneumoniae recovered from ongoing surveillance in Brazil. Fam I and Fam2 were expressed in comparable rates among 366 isolates, with the potential coverage of 94.3%. PspA families were not associated to age group or source of isolates. However, considering the significant tendency of increasing prevalence of Fam2 associated to widespread dissemination of the genetically-related resistant strains, the monitoring of the PspA families derived from population-based data may be necessary in the context of vaccine development. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3890 / 3896
页数:7
相关论文
共 31 条
[1]   Pneumococcal resistance to beta-lactam antibiotics: A global geographic overview [J].
Baquero, F .
MICROBIAL DRUG RESISTANCE, 1995, 1 (02) :115-120
[2]   Pneumococcal pspA sequence types of prevalent multiresistant pneumococcal strains in the United States and of internationally disseminated clones [J].
Beall, B ;
Gherardi, G ;
Facklam, RR ;
Hollingshead, SK .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (10) :3663-3669
[3]   Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children [J].
Black, S ;
Shinefield, H ;
Fireman, B ;
Lewis, E ;
Ray, P ;
Hansen, JR ;
Elvin, L ;
Ensor, KM ;
Hackell, J ;
Siber, G ;
Malinoski, F ;
Madore, D ;
Chang, I ;
Kohberger, R ;
Watson, W ;
Austrian, R ;
Edwards, K .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) :187-195
[4]   Appropriateness of a pneumococcal conjugate vaccine in Brazil: Potential impact of age and clinical diagnosis, with emphasis on meningitis [J].
Brandileone, MCC ;
de Andrade, ALSS ;
Di Fabio, JL ;
Guerra, MLLS ;
Austrian, R .
JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (08) :1206-1212
[5]  
Brandileone MCD, 1998, MICROB DRUG RESIST, V4, P209
[6]   The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection [J].
Briles, DE ;
Hollingshead, S ;
Brooks-Walter, A ;
Nabors, GS ;
Ferguson, L ;
Schilling, M ;
Gravenstein, S ;
Braun, P ;
King, J ;
Swift, A .
VACCINE, 2000, 18 (16) :1707-1711
[7]   Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae [J].
Briles, DE ;
Ades, E ;
Paton, JC ;
Sampson, JS ;
Carlone, GM ;
Huebner, RC ;
Virolainen, A ;
Swiatlo, E ;
Hollingshead, SK .
INFECTION AND IMMUNITY, 2000, 68 (02) :796-800
[8]   Pneumococcal diversity: Considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA) [J].
Briles, DE ;
Tart, RC ;
Swiatlo, E ;
Dillard, JP ;
Smith, P ;
Benton, KA ;
Ralph, BA ;
Brooks-Walter, A ;
Crain, MJ ;
Hollingshead, SK ;
McDaniel, LS .
CLINICAL MICROBIOLOGY REVIEWS, 1998, 11 (04) :645-+
[9]   The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae [J].
Briles, DE ;
Hollingshead, SK ;
Nabors, GS ;
Paton, JC ;
Brooks-Walter, A .
VACCINE, 2000, 19 :S87-S95
[10]  
Coral MCV, 2001, EMERG INFECT DIS, V7, P832